Disease Management in Individuals with Phenylketonuria

Year 2024, Volume: 14 Issue: 2, 572 - 581, 28.06.2024

Esra Gül , Ayşe Güneş Bayır

https://doi.org/10.33808/clinexphealthsci.1360624

Abstract

Phenylketonuria (PKU), one of the most common metabolic diseases, is a recessive, congenital and hereditary disease that occurs with the absence or deficiency of the enzyme called phenylalanine hydroxylase, which converts phenylalanine to tyrosine. Therefore, the aim of this review was to discuss the disease management in individuals with phenylketonuria. As a result of the inability to metabolize phenylalanine amino acid in patients with PKU, the level of phenylalanine increases in the systemic circulation and brain, which may lead to neurocognitive activity and psychosocial dysfunctions and various disorders. If infants with PKU, who are indistinguishable from healthy babies at first birth, are fed like normal babies, phenylalanine accumulates in the body and symptoms occur and gradually worsen. To keep the blood sugar phenylalanine level at the desired range various medical treatment methods (pharmacological treatment and gene therapy), especially nutritional therapy, can be preferred. However, alternative treatment methods should be carried out in combination with diet therapy. Some dietary restrictions are maintained for life, while patients follow a strict diet in dietary protein intake to prevent high plasma phenylalanine levels and neurological damage. In this review, the definition, classification and phenylalanine-restricted diet treatments of phenylketonuria are discussed.

Keywords

Phenylketonuria, phenylalanine restriction, phenylalanine hycroxylase, enzyme deficiency, nutritional therapy

References

• MacDonald A, van Wegberg AMJ, Ahring K, Beblo S, Bélanger-Quintana A, Burlina A, Campistol J, Coşkun T, Feillet F, Giżewska M, Huijbregts SC, Leuzzi V, Maillot F, Muntau AC, Rocha JC, Romani C, Trefz F, van Spronsen FJ. PKU dietary handbook to accompany PKU guidelines. Orphanet J Rare Dis. 2020;15(1):171. DOI:10.1186/s13023-020-01391-y
• Dijkstra AM, van Vliet N, van Vliet D, Romani C, Huijbregts SCJ, van der Goot E, Hovens IB, van der Zee EA, Kema IP, Heiner-Fokkema MR, van Spronsen FJ. Correlations of blood and brain biochemistry in phenylketonuria: Results from the Pah-enu2 PKU mouse. Mol Genet Metab. 2021;134(3):250-256. DOI:10.1016/j.ymgme.2021.09.004
• Brown CS, Lichter-Konecki U. Phenylketonuria (PKU): A problem solved?. Mol Genet Metab Rep. 2015;6:8-12. DOI:10.1016/j.ymgmr.2015.12.004
• van Calcar SC, Ney DM. Food products made with glycomacropeptide, a low-phenylalanine whey protein, provide a new alternative to amino Acid-based medical foods for nutrition management of phenylketonuria. J Acad Nutr Diet. 2012;112(8):1201-1210. DOI:10.1016/j.jand.2012.05.004
• Blau N, van Spronsen FJ, Levy HL. Phenylketonuria. Lancet. 2010;376(9750):1417-1427. DOI:10.1016/S0140-6736(10)60961-0
• Evans S, Daly A, Chahal S, MacDonald J, MacDonald A. Food acceptance and neophobia in children with phenylketonuria: a prospective controlled study. J Hum Nutr Diet. 2016;29(4):427-433. DOI:10.1111/jhn.12346
• Williams RA, Mamotte CD, Burnett JR. Phenylketonuria: An inborn error of phenylalanine metabolism. Clin Biochem Rev. 2008;29(1):31-41.
• Millington DS, Kodo N, Norwood DL, Roe CR. Tandem mass spectrometry: a new method for acylcarnitine profiling with potential for neonatal screening for inborn errors of metabolism. J Inherit Metab Dis. 1990;13(3):321-324. DOI:10.1007/BF01799385
• Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, Mitchell J, Smith WE, Thompson BH, Berry SA; American College of Medical Genetics and Genomics Therapeutics Committee. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16(2):188-200. DOI:10.1038/gim.2013.157
• Al Hafid N, Christodoulou J. Phenylketonuria: A review of current and future treatments. Transl Pediatr. 2015;4(4):304-317. DOI:10.3978/j.issn.2224-4336.2015.10.07
• ten Hoedt AE, de Sonneville LM, Francois B, ter Horst NM, Janssen MC, Rubio-Gozalbo ME, Wijburg FA, Hollak CE, Bosch AM. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: A randomised, double-blind, placebo-controlled, crossover trial. J Inherit Metab Dis. 2011;34(1):165-171. DOI:10.1007/s10545-010-9253-9
• Mitchell JJ, Trakadis YJ, Scriver CR. Phenylalanine hydroxylase deficiency. Genet Med. 2011;13(8):697-707. DOI:10.1097/GIM.0b013e3182141b48
• American Academy of Pediatrics; Rose SR; Section on Endocrinology and Committee on Genetics, American Thyroid Association; Brown RS; Public Health Committee, Lawson Wilkins Pediatric Endocrine Society; Foley T, Kaplowitz PB, Kaye CI, Sundararajan S, Varma SK. Update of newborn screening and therapy for congenital hypothyroidism. Pediatrics 2006;117(6):2290-2303. DOI:10.1542/peds.2006-0915
• Ashe K, Kelso W, Farrand S, Panetta J, Fazio T, De Jong G, Walterfang M. Psychiatric and cognitive aspects of phenylketonuria: the limitations of diet and promise of new treatments. Front Psychiatry 2019;10:561. DOI:10.3389/fpsyt.2019.00561
• van Wegberg AMJ, MacDonald A, Ahring K, Bélanger-Quintana A, Blau N, Bosch AM, Burlina A, Campistol J, Feillet F, Giżewska M, Huijbregts SC, Kearney S, Leuzzi V, Maillot F, Muntau AC, van Rijn M, Trefz F, Walter JH, van Spronsen FJ. The Complete European guidelines on phenylketonuria: Diagnosis and treatment. Orphanet J Rare Dis. 2017;12(1):162. DOI:10.1186/s13023-017-0685-2
• Blau N, Bélanger-Quintana A, Demirkol M, Feillet F, Giovannini M, MacDonald A, Trefz FK, van Spronsen FJ. Optimizing the use of sapropterin (BH(4) in the management of phenylketonuria. Mol Genet Metab. 2009;96(4):158-163. DOI:10.1016/j.ymgme.2009.01.002
• Mahan KC, Gandhi MA, Anand S. Pegvaliase: A novel treatment option for adults with phenylketonuria. Curr Med Res Opin. 2019;35(4):647-651. DOI:10.1080/03007995.2018.1528215
• Banta-Wright SA, Shelton KC, Lowe ND, Knafl KA, Houck GM. Breast-feeding success among infants with phenylketonuria. J Pediatr Nurs. 2012;27(4):319-327. DOI:10.1016/j.pedn.2011.03.015
• Al Hafid N, Christodoulou J. Phenylketonuria: A review of current and future treatments. Transl Pediatr. 2015;4(4):304-317. DOI:10.3978/j.issn.2224-4336.2015.10.07
• Strisciuglio P, Concolino D. New Strategies for the Treatment of Phenylketonuria (PKU). Metabolites. 2014;4(4):1007–1017. DOI:10.3390/metabo4041007
• Sailer M, Elizondo G, Martin J, Harding CO, Gillingham MB. Nutrient intake, body composition, and blood phenylalanine control in children with phenylketonuria compared to healthy controls. Mol Genet Metab Rep. 2020;23:100599. DOI:10.1016/j.ymgmr.2020.100599
• van Spronsen FJ, van Rijn M, Bekhof J, Koch R, Smit PG. Phenylketonuria: Tyrosine supplementation in phenylalanine-restricted diets. Am J Clin Nutr. 2001;73(2):153-157. DOI:10.1093/ajcn/73.2.153
• Firman S, Witard OC, O'Keeffe M, Ramachandran R. Dietary protein and protein substitute requirements in adults with phenylketonuria: A review of the clinical guidelines. Clin Nutr. 2021;40(3):702-709. DOI:10.1016/j.clnu.2020.11.003
• MacDonald A, Rocha JC, van Rijn M, Feillet F. Nutrition in phenylketonuria. Mol Genet Metab. 2011;104 Suppl:S10-S18. DOI:10.1016/j.ymgme.2011.08.023
• Elhawary NA, AlJahdali IA, Abumansour IS, Elhawary EN, Gaboon N, Dandini M, Madkhali A, Alosaimi W, Alzahrani A, Aljohani F, Melibary EM, Kensara OA. Genetic etiology and clinical challenges of phenylketonuria. Hum Genomics 2022;16(1):22. DOI: 10.1186/s40246-022-00398-9.
• Newbould E, Pinto A, Evans S, Ford S, O'Driscoll M, Ashmore C, Daly A, MacDonald A. Accidental Consumption of Aspartame in Phenylketonuria: Patient Experiences. Nutrients. 2021;13(2):707. DOI:10.3390/nu13020707
• Araújo ACMF, Araújo WMC, Marquez UML, Akutsu R, Nakano EY. Table of Phenylalanine Content of Foods: Comparative Analysis of Data Compiled in Food Composition Tables. JIMD Rep. 2017;34:87-96. DOI:10.1007/8904_2016_12
• Sanford M, Keating GM. Sapropterin: a review of its use in the treatment of primary hyperphenylalaninaemia. Drugs. 2009;69(4):461-476. DOI:10.2165/00003495-200969040-00006
• Dokoupil K, Gokmen-Ozel H, Lammardo AM, Motzfeldt K, Robert M, Rocha JC, van Rijn M, Ahring K, Bélanger-Quintana A, MacDonald A. Optimising growth in phenylketonuria: current state of the clinical evidence base. Clin Nutr. 2012;31(1):16-21. DOI:10.1016/j.clnu.2011.09.001
• Ahring K, Bélanger-Quintana A, Dokoupil K, Gokmen Ozel H, Lammardo AM, MacDonald A, Motzfeldt K, Nowacka M, Robert M, van Rijn M. Dietary management practices in phenylketonuria across European centres. Clin Nutr. 2009;28(3):231-236. DOI:10.1016/j.clnu.2009.03.004
• MacDonald A, Asplin D. Phenylketonuria: practical dietary management. J Fam Health Care. 2006;16(3):83-85.
• Camp KM, Parisi MA, Acosta PB, Berry GT, Bilder DA, Blau N, Bodamer OA, Brosco JP, Brown CS, Burlina AB, Burton BK, Chang CS, Coates PM, Cunningham AC, Dobrowolski SF, Ferguson JH, Franklin TD, Frazier DM, Grange DK, Greene CL, Groft SC, Harding CO, Howell RR, Huntington KL, Hyatt-Knorr HD, Jevaji IP, Levy HL, Lichter-Konecki U, Lindegren ML, Lloyd-Puryear MA, Matalon K, MacDonald A, McPheeters ML, Mitchell JJ, Mofidi S, Moseley KD, Mueller CM, Mulberg AE, Nerurkar LS, Ogata BN, Pariser AR, Prasad S, Pridjian G, Rasmussen SA, Reddy UM, Rohr FJ, Singh RH, Sirrs SM, Stremer SE, Tagle DA, Thompson SM, Urv TK, Utz JR, van Spronsen F, Vockley J, Waisbren SE, Weglicki LS, White DA, Whitley CB, Wilfond BS, Yannicelli S, Young JM. Phenylketonuria Scientific Review Conference: State of the science and future research needs. Mol Genet Metab. 2014;112(2):87-122. DOI:10.1016/j.ymgme.2014.02.013
• Kose E, Aksoy B, Kuyum P, Tuncer N, Arslan N, Ozturk Y. The Effects of Breastfeeding in Infants With Phenylketonuria. J Pediatr Nurs. 2018;38:27-32. DOI:10.1016/j.pedn.2017.10.009
• Carpenter K, Wittkowski A, Hare DJ, Medford E, Rust S, Jones SA, Smith DM. Parenting a Child with Phenylketonuria (PKU): An Interpretative Phenomenological Analysis (IPA) of the Experience of Parents. J Genet Couns. 2018;27(5):1074-1086. DOI:10.1007/s10897-018-0227-7
• Haitjema S, Lubout CMA, Abeln D, Bruijn-van der Veen M, MacDonald A, Wolffenbuttel BHR, van Spronsen FJ. Dietary treatment in Dutch children with phenylketonuria: An inventory of associated social restrictions and eating problems. Nutrition. 2022;97:111576. DOI:10.1016/j.nut.2021.111576
• Evans S, Daly A, Chahal S, Ashmore C, MacDonald J, MacDonald A. The influence of parental food preference and neophobia on children with phenylketonuria (PKU). Mol Genet Metab Rep. 2017;14:10-14. DOI:10.1016/j.ymgmr.2017.10.007
• Mira NV, Marquez UM. Importância do diagnóstico e tratamento da fenilcetonúria [Importance of the diagnoses and treatment of phenylketonuria]. Rev Saude Publica. 2000;34(1):86-96. DOI:10.1590/s0034-89102000000100016. Makale dili?
• de Groot MJ, Hoeksma M, Blau N, Reijngoud DJ, van Spronsen FJ. Pathogenesis of cognitive dysfunction in phenylketonuria: review of hypotheses. Mol Genet Metab. 2010;99 Suppl 1:S86-S89. DOI:10.1016/j.ymgme.2009.10.016
• Schuck PF, Malgarin F, Cararo JH, Cardoso F, Streck EL, Ferreira GC. Phenylketonuria Pathophysiology: on the Role of Metabolic Alterations. Aging Dis. 2015;6(5):390-399. DOI:10.14336/AD.2015.0827
• de Groot MJ, Sijens PE, Reijngoud DJ, Paans AM, van Spronsen FJ. Phenylketonuria: brain phenylalanine concentrations relate inversely to cerebral protein synthesis. J Cereb Blood Flow Metab. 2015;35(2):200-205. DOI:10.1038/jcbfm.2014.183
• Preiser JC. Oxidative stress. J Parenter Enteral Nutr. 2012;36(2):147-154. DOI:10.1177/0148607111434963
• Nagasaka H, Tsukahara H, Okano Y, Hirano K, Sakurai T, Hui SP, Ohura T, Usui H, Yorifuji T, Hirayama S, Ohtake A, Miida T. Changes of lipoproteins in phenylalanine hydroxylase-deficient children during the first year of life. Clin Chim Acta. 2014;433:1-4. DOI:10.1016/j.cca.2014.02.020
• van Spronsen FJ, Blau N, Harding C, Burlina A, Longo N, Bosch AM. Phenylketonuria. Nat Rev Dis Primers. 2021;7(1):36. DOI:10.1038/s41572-021-00267-0
• Boot E, Hollak CEM, Huijbregts SCJ, Jahja R, van Vliet D, Nederveen AJ, Nieman DH, Bosch AM, Bour LJ, Bakermans AJ, Abeling NGGM, Bassett AS, van Amelsvoort TAMJ, van Spronsen FJ, Booij J. Cerebral dopamine deficiency, plasma monoamine alterations and neurocognitive deficits in adults with phenylketonuria. Psychol Med. 2017;47(16):2854-2865. DOI:10.1017/S0033291717001398
• González MJ, Gassió R, Artuch R, Campistol J. Impaired Neurotransmission in Early-treated Phenylketonuria Patients. Semin Pediatr Neurol. 2016;23(4):332-340. DOI:10.1016/j.spen.2016.11.007
• Palermo L, Geberhiwot T, MacDonald A, Limback E, Hall SK, Romani C. Cognitive outcomes in early-treated adults with phenylketonuria (PKU): A comprehensive picture across domains. Neuropsychology. 2017;31(3):255-267. DOI:10.1037/neu0000337
• Burton BK, Leviton L, Vespa H, Coon H, Longo N, Lundy BD, Johnson M, Angelino A, Hamosh A, Bilder D. A diversified approach for PKU treatment: Routine screening yields high incidence of psychiatric distress in phenylketonuria clinics. Mol Genet Metab. 2013;108(1):8-12. DOI:10.1016/j.ymgme.2012.11.003
• Jahja R, Huijbregts SCJ, de Sonneville LMJ, van der Meere JJ, Legemaat AM, Bosch AM, Hollak CEM, Rubio-Gozalbo ME, Brouwers MCGJ, Hofstede FC, de Vries MC, Janssen MCH, van der Ploeg AT, Langendonk JG, van Spronsen FJ. Cognitive profile and mental health in adult phenylketonuria: A PKU-COBESO study. Neuropsychology. 2017;31(4):437-447. DOI:10.1037/neu0000358
• Bilder DA, Noel JK, Baker ER, Irish W, Chen Y, Merilainen MJ, Prasad S, Winslow BJ. Systematic Review and Meta-Analysis of Neuropsychiatric Symptoms and Executive Functioning in Adults With Phenylketonuria. Dev Neuropsychol. 2016;41(4):245-260. DOI:10.1080/87565641.2016.1243109
• Vardy ERLC, MacDonald A, Ford S, Hofman DL. Phenylketonuria, co-morbidity, and ageing: A review. J Inherit Metab Dis. 2020;43(2):167-178. DOI:10.1002/jimd.12186
• Solverson P, Murali SG, Brinkman AS, Nelson DW, Clayton MK, Yen CL, Ney DM. Glycomacropeptide, a low-phenylalanine protein isolated from cheese whey, supports growth and attenuates metabolic stress in the murine model of phenylketonuria. Am J Physiol Endocrinol Metab. 2012;302(7):E885-E895. DOI:10.1152/ajpendo.00647.2011
• Demirdas S, Coakley KE, Bisschop PH, Hollak CE, Bosch AM, Singh RH. Bone health in phenylketonuria: a systematic review and meta-analysis. Orphanet J Rare Dis. 2015;10:17. DOI:10.1186/s13023-015-0232-y
• Howard C, Ferrucci L, Sun K, Fried LP, Walston J, Varadhan R, Guralnik JM, Semba RD. Oxidative protein damage is associated with poor grip strength among older women living in the community. J Appl Physiol. 2007;103(1):17-20. DOI:10.1152/japplphysiol.00133.2007
• Paddon-Jones D, Rasmussen BB. Dietary protein recommendations and the prevention of sarcopenia. Curr Opin Clin Nutr Metab Care. 2009;12(1):86-90. DOI:10.1097/MCO.0b013e32831cef8b
• Pakula MM, Maier TJ, Vorup-Jensen T. Insight on the impacts of free amino acids and their metabolites on the immune system from a perspective of inborn errors of amino acid metabolism. Expert Opin Ther Targets. 2017;21(6):611-626. DOI:10.1080/14728222.2017.1323879
• Brown AS, Fernhoff PM, Waisbren SE, Frazier DM, Singh R, Rohr F, Morris JM, Kenneson A, MacDonald P, Gwinn M, Honein M, Rasmussen SA. Barriers to successful dietary control among pregnant women with phenylketonuria. Genet Med. 2002;4(2):84-89. DOI:10.1097/00125817-200203000-00006
• Lee PJ, Ridout D, Walter JH, Cockburn F. Maternal phenylketonuria: Report from the United Kingdom Registry 1978-97. Arch Dis Child. 2005;90(2):143-146. DOI:10.1136/adc.2003.037762
• Rocha JC, van Dam E, Ahring K, Almeida MF, Bélanger-Quintana A, Dokoupil K, Gökmen-Özel H, Robert M, Heidenborg C, Harbage E, MacDonald A. A series of three case reports in patients with phenylketonuria performing regular exercise: first steps in dietary adjustment. J Pediatr Endocrinol Metab. 2019;32(6):635-641. DOI:10.1515/jpem-2018-0492
• Mazzola PN, Teixeira BC, Schirmbeck GH, Reischak-Oliveira A, Derks TGJ, van Spronsen FJ, Dutra-Filho CS, Schwartz IVD. Acute exercise in treated phenylketonuria patients: Physical activity and biochemical response. Mol Genet Metab Rep. 2015;5:55-59. DOI:10.1016/j.ymgmr.2015.10.003